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endoplasmic reticulum stress
Sian E. Piret1, Eric Olinger2, Anita A. C. Reed1, M. Andrew Nesbit1,3, Tertius A. Hough4, Liz Bentley4,
Olivier Devuyst2, Roger D. Cox4 and Rajesh V. Thakker1,*
ABSTRACT
Renal fibrosis is a common feature of renal failure resulting from
multiple etiologies, including diabetic nephropathy, hypertension and
inherited renal disorders. However, the mechanisms of renal fibrosis
are incompletely understood and we therefore explored these by
establishing amousemodel for a renal tubular disorder, referred to as
autosomal dominant tubulointerstitial kidney disease (ADTKD) due to
missense uromodulin (UMOD) mutations (ADTKD-UMOD). ADTKD-
UMOD, which is associated with retention of mutant uromodulin in the
endoplasmic reticulum (ER) of renal thick ascending limb cells, is
characterized by hyperuricemia, interstitial fibrosis, inflammation and
renal failure, and we used targeted homologous recombination to
generate a knock-in mouse model with an ADTKD-causing missense
cysteine to arginine uromodulinmutation (C125R). Heterozygous and
homozygous mutant mice developed reduced uric acid excretion,
renal fibrosis, immune cell infiltration and progressive renal failure,
with decreased maturation and excretion of uromodulin, due to its
retention in the ER. The ER stress marker 78 kDa glucose-regulated
protein (GRP78) was elevated in cells expressing mutant uromodulin
in heterozygous and homozygous mutant mice, and this was
accompanied, both in vivo and ex vivo, by upregulation of two
unfolded protein response pathways in primary thick ascending limb
cells from homozygous mutant mice. However, this did not lead to an
increase in apoptosis in vivo. Thus, we have developed a novel
mouse model for renal fibrosis, which will be a valuable resource to
decipher the mechanisms linking uromodulin mutations with ER
stress and renal fibrosis.
KEY WORDS: Kidney, Fibrosis, ER stress, Mouse model,
Endoplasmic reticulum
INTRODUCTION
Renal fibrosis is an integral factor in progression to end-stage
renal failure (ESRF), regardless of the primary etiology, which
may include diabetic nephropathy, hypertension or monogenic
disorders (Eddy, 2014). However, mechanisms of renal fibrosis are
incompletely understood, and there are currently no therapies to
reverse or slow down the progression of renal fibrosis (Eddy, 2014).
Autosomal dominant tubulointerstitial kidney disease (ADTKD), a
monogenic cause of renal fibrosis, is characterized by urine
concentrating defects, interstitial nephropathy with immune cell
infiltration and glomerulosclerosis, and progressive loss of renal
function leading to ESRF (Eckardt et al., 2015). Mutations in four
genes have been identified to cause ADTKD, with the most
common being in the UMOD gene, encoding uromodulin (Eckardt
et al., 2015; Hart et al., 2002; Turner et al., 2003), referred to as
ADTKD-UMOD. ADTKD-UMOD was previously referred to as
familial juvenile hyperuricemic nephropathy type 1 (FJHN1;
OMIM #162000), medullary cystic kidney disease type 2
(MCKD2; OMIM #603860) and glomerulocystic kidney disease
(GCKD; OMIM #609886) (Eckardt et al., 2015; Rampoldi et al.,
2003). In addition to the general clinical characteristics of ADTKD,
patients with ADTKD-UMOD present with elevated serum urate
concentrations due to low fractional excretion of uric acid (FEUA).
Uromodulin, a 640 amino acid glycosylphosphatidylinositol
(GPI) anchored protein, is only expressed in the thick ascending
limb (TAL) of the loop of Henle (Rampoldi et al., 2011).
Uromodulin is synthesized within the endoplasmic reticulum
(ER), trafficked to the apical plasma membrane, cleaved into the
tubule and excreted in the urine, where it is the most abundant
protein (Rampoldi et al., 2011). Uromodulin likely contains: four
epidermal growth factor (EGF)-like domains, of which the second
and third are calcium-binding (cb) EGF domains; a cysteine-rich
region, which includes a domain of eight cysteines; and a zona
pellucida (ZP) domain (Bokhove et al., 2016) (Fig. S1). Several
functions have been postulated for uromodulin, including:
regulating sodium transport in the TAL by modulating the activity
of the apical transporters NKCC2 and ROMK (renal outer
medullary potassium channel) (Trudu et al., 2013); inhibiting
renal stone formation; preventing bacterial colonization; and
modulating immune responses (Bates et al., 2004; Darisipudi
et al., 2012; Mattey and Naftalin, 1992; Mo et al., 2004a,b, 2007;
Raffi et al., 2009, 2005; Säemann et al., 2005a,b).
Over 90% of the >55 reported ADTKD-UMOD mutations are
missense, suggesting a dominant negative disease mechanism, and
>60% cause loss or gain of a cysteine residue (Moskowitz et al.,
2013), implicating a role for protein misfolding in ADTKD-UMOD.
Most mutations are clustered in the EGF domains and cysteine-rich
region, which are likely involved in formation of most of the 24
disulfide bridges in uromodulin (Rampoldi et al., 2011), and
uromodulin missense mutations cause altered intracellular
trafficking, with retention of immature, core-glycosylated
uromodulin in the ER, resulting in reduced or absent expression at
the plasma membrane with little or no secretion (Bernascone et al.,
2006; Choi et al., 2005; Dahan et al., 2003; Jennings et al., 2007;
Rampoldi et al., 2003; Vylet’al et al., 2006; Williams et al., 2009).Received 6 February 2017; Accepted 2 March 2017
1Academic Endocrine Unit, University of Oxford, Oxford Centre for Diabetes,
Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ,
UK. 2Institute of Physiology, University of Zurich, Zurich CH-8057, Switzerland.
3School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK.
4MRC Mammalian Genetics Unit and Mary Lyon Centre, MRC Harwell Institute,
Harwell Science and Innovation Campus, Oxfordshire OX11 0RD, UK.
*Author for correspondence (rajesh.thakker@ndm.ox.ac.uk)
R.V.T., 0000-0002-1438-3220
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
773
© 2017. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2017) 10, 773-786 doi:10.1242/dmm.029488
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
However, the role of uromodulin mutations in causing renal
interstitial fibrosis, glomerulosclerosis and immune cell infiltration
is not fully understood.
ER accumulation of mutant proteins can cause ER stress, which
activates the unfolded protein response (UPR), which may be
adaptive or apoptotic in different tissues (Tsang et al., 2010), and
consists of three pathways: the activating transcription factor-6α
(ATF6α), inositol-requiring enzyme-1 (IRE1) and RNA-activated
protein kinase-like ER kinase (PERK) pathways. These act to
upregulate chaperones and ER-associated degradation (ERAD)
components, and reduce global protein translation to decrease the
ER protein load. Under prolonged and unresolved ER stress, cells
may also undergo apoptosis (Tsang et al., 2010). The ER stress-
induced chaperone 78 kDa glucose-regulated protein [GRP78; also
known as binding immunoglobulin protein (BiP)] is upregulated in
renal biopsies from patients harboring mutations in UMOD (Adam
et al., 2012); however, mechanisms of ER stress and the UPR
pathways have not been studied further in ADTKD.
Two Umod mouse knock-out models have been developed,
which have revealed roles for uromodulin in: defense against
bladder and urinary tract bacterial infections (Bates et al., 2004; Mo
et al., 2004b; Raffi et al., 2009, 2005); prevention of renal stone
formation (Liu et al., 2010; Mo et al., 2004a, 2007); and water
impermeability and solute handling in the TAL (Bachmann et al.,
2005; Mutig et al., 2011; Renigunta et al., 2011; Wolf et al., 2013).
However,Umod knock-out mice up to 3 years of age do not develop
any of the histological features or renal failure characteristic of
ADTKD (Raffi et al., 2006). A transgenic mouse model carrying a
human UMOD transgene containing the ADTKD-UMOD-causing
mutation Cys148Trp (C148W) in addition to the two mouse Umod
alleles was not reported to have renal impairment or abnormal renal
histology (Takiue et al., 2008a,b) (Table S1). However, a second
transgenic mouse expressing mouse Umod with the C148W
mutation developed several features of ADTKD-UMOD,
including mild renal failure, urinary concentrating defects, and
interstitial inflammation and fibrosis, but decreased uric acid
excretion was not reported (Bernascone et al., 2010) (Table S1).
Thus, two similar transgenic models demonstrated two different
phenotypes and, since in both models uromodulin was
overexpressed compared to in non-transgenic mice, these models
require cautious interpretation. An N-ethyl-N-nitrosourea (ENU)-
generated uromodulin mutant [Ala227Thr (A227T)] mouse has
been described to develop azotemia, impaired urine concentrating
ability and reduced excretion of uric acid, but not renal fibrosis
(Kemter et al., 2009), whilst a second ENU mutant, Cys93Phe
(C93F), developed renal failure, urinary concentrating defects,
interstitial fibrosis, inflammation and tubular defects (Kemter et al.,
2013) (Table S1). However, neither A227T nor C93F are known
disease-causing mutations in humans.
In order to study mechanisms of renal fibrosis, ADTKD-UMOD
and ER stress due to uromodulin mutations relevant to ADTKD-
UMOD in humans, we generated a targeted mouse knock-in model
by homologous recombination in mouse embryonic stem (ES) cells,
to produce mice carrying a known disease-causing mutation,
Cys125Arg (C125R), within the mouse Umod gene. Cysteine 125
(C125) is located within the cbEGF3 domain of uromodulin,
and mutation of this residue likely disrupts formation of the
Ca2+-binding pocket which is formed by a set pattern of disulfide
bonding within this domain (Turner et al., 2003) (Fig. S1). C125 in
mouse uromodulin is the equivalent of C126 in human uromodulin,
and mutation of this residue in humans to an arginine (C126R) has
been reported to cause ADTKD-UMOD (Lhotta et al., 1998; Turner
et al., 2003). Furthermore, C126R uromodulin is retained in the ER
of transfected cells (Williams et al., 2009), which is typical of
several uromodulin mutations that have been characterized in vitro
(Bernascone et al., 2006; Choi et al., 2005; Jennings et al., 2007;
Rampoldi et al., 2003; Vylet’al et al., 2006; Williams et al., 2009).
This mutation was therefore selected as being representative of the
majority of disease-causing uromodulin mutations.
RESULTS
Introduction of C125R mutation into the mouse germline
A targeting vector containing 7.6 kb of the mouse Umod gene, with
the C125R mutation in exon 3, a thymidine kinase (TK) cassette at
the 5′ end and a neomycin resistance (NeoR) cassette in intron 2, was
used to introduce the C125R mutation into the mouse genome by
homologous recombination in ES cells (Fig. S1). Of 272 ES cell
clones that were selection resistant, 5 clones, termed B6, C2, D11,
E10 and H10, were shown to have undergone homologous
recombination at the 5′ and 3′ ends of the targeting construct by
PCR/restriction assay (data not shown) and Southern blot analysis
(Fig. 1A). Blastocyst injection of clone C2 resulted in the birth of
chimeras with a high degree of chimerism (>∼90%). Male chimeras
were bred with C57BL/6J females and the mutation was shown
to enter the germline by genotyping of mice using PCR and
BsoBI restriction digest (Fig. 1B). Germline mutant mice were bred
with β-actin-Cre mice to excise the NeoR cassette. Heterozygous
(Umod+/125R) and homozygous (Umod125R/125R) mutant mice were
viable and fertile, with appearances and body weights (Table 1)
similar to wild-type (Umod+/+) mice.
Plasma biochemistry in 8-week- and 6-month-old Umod+/+,
Umod+/125R and Umod125R/125R mice
Male (P<0.001) and female (P<0.01) Umod125R/125R mice had
plasma urea levels ∼2-fold greater than those of Umod+/+ and
Umod+/125R littermates at 8 weeks of age (Table 1). By 6 months of
age, plasma urea levels were increased ∼1.5-fold and ∼2.5-fold in
Umod+/125R (male P<0.0001; female P<0.01) and Umod125R/125R
(male P<0.0001; female P<0.0001) mice, respectively, compared to
Umod+/+ littermates (Table 1). Plasma urea increased between
8-week- and 6-month-oldUmod+/125Rmice by∼1.8-fold (P<0.0001)
in males and ∼1.2-fold (P<0.05) in females, demonstrating
progressive renal failure (Table 1). Plasma creatinine was also
significantly raised, by ∼1.5-fold and ∼1.8-fold, in 6-month-old
Umod+/125R (P<0.05) and Umod125R/125R (P<0.001) males,
respectively, and by ∼1.2-fold in Umod125R/125R females
(P<0.05) compared to age and sex matched Umod+/+ littermates
(Table 1). Male and female 6-month-old Umod125R/125R mice also
had significantly raised plasma corrected calcium concentrations
(P<0.01) compared to Umod+/+ littermates, which, in conjunction
with a significantly raised plasma alkaline phosphatase (ALP)
activity (males P<0.001; females P<0.01), is consistent with the
likely onset of tertiary hyperparathyroidism (Table 1). However, this
hypercalcemia in association with raised plasma ALP activity in the
Umod125R/125R mice, which has also previously been reported in
two ENU-induced mutant mouse models with A227T and C93F
Umod mutations (Kemter et al., 2009, 2013) (Table S1), has not
been observed to occur in ADTKD-UMOD patients who develop
renal failure. A plausible explanation for this occurrence of
hypercalcemia, likely due to tertiary hyperparathyroidism, in
Umod mutant mice but not ADTKD-UMOD patients is that the
earlier detection of renal failure and associated secondary
hyperparathyroidism, with appropriate treatment using vitamin D
analogs, phosphate binders and calcimimetics, will prevent the
774
RESEARCH ARTICLE Disease Models & Mechanisms (2017) 10, 773-786 doi:10.1242/dmm.029488
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
progression to tertiary hyperparathyroidism in patients. Plasma uric
acid levels were not increased in Umod+/125R or Umod125R/125R
mice at 8 weeks or 6 months, likely due to expression of the hepatic
enzyme uricase in mice (Wu et al., 1992). Plasma sodium and
potassium concentrations were similar in mutant and wild-type mice
(data not shown).
Urine biochemistry in 8-week- and 6-month-old Umod+/+,
Umod+/125R and Umod125R/125R mice
Male and femaleUmod125R/125R mice excreted ∼2–4-fold increased
volumes of urine (corrected for body weight) (P<0.0001), and this
urine was more dilute with ∼2–4-fold decreased urine osmolality
(8-week-old males and 6-month-old males and females P<0.0001;
Fig. 1. Uromodulin maturation, excretion and trafficking. (A) Homologous recombination in ES cell clones assessed by Southern blot analysis: DNA from 5
clones (B6, C2, D11, E10, H10) and awild-type (WT) control underwent SpeI digestion, generating products of ∼8.3 kb [wild-type (W) allele] and ∼9.6 kb [mutant
(m) allele]. The probe for detection spanned Umod exon 6. (B) Genotyping of mice: the C125R mutation introduced an additional BsoBI site, which was used
to digest PCR products of part of exon 3, leaving the wild-type (W) 144 bp product uncut, and cleaving the mutant product into 116 bp (m) and 38 bp (not
shown) fragments. Digests from two each of wild-type (+/+), heterozygous (+/125R) and homozygous mutant (125R/125R) mice are shown. (C) Western blot
analysis of whole kidney lysates fromUmod+/+,Umod+/125R andUmod125R/125Rmalemice aged 8 weeks (top) and 6 months (bottom).Umod+/+ mice had only the
mature form (M) of uromodulin (U), butUmod+/125R andUmod125R/125R mice had varying amounts of the precursor form (P), and high molecular mass uromodulin
that may be dimers of the precursor. Tubulin (T) was used as a control. For technical reasons, in the lower panel of C, the same lysates were blotted for uromodulin
and tubulin on two different gels. (D) Representative western blots of urine from males aged 8 weeks (upper blot) and 6 months (lower blot), with densitometric
analysis. Umod+/+ and Umod+/125R samples diluted 1/20; Umod125R/125R samples undiluted. Densitometric measurements are plotted relative to mean of
Umod+/+ densities (set to 100%). Umod+/+: black bars; Umod+/125R: gray bars; Umod125R/125R: white bars. Values shown as mean+s.e.m.; n=9 for 8-week-old
females, n=8 for 8-week-old males, n=7 for 6-month-old Umod+/+ females, n=8 for 6-month-old Umod+/125R and Umod125R/125R females, n=10 for 6-month-old
Umod+/+ males, n=12 for 6-month-old Umod+/125R males, n=6 for 6-month-old Umod125R/125R males. *P<0.001, **P<0.00001 versus Umod+/+ littermates of the
same age and sex. $P<0.05, $$P<0.00001 versus 8-week-old mice of the same sex and genotype (Student’s unpaired 1-tailed t-test). (E) Immunohistochemical
analysis of uromodulin showing apical expression in Umod+/+ mice, partial intracellular retention in Umod+/125R mice, and dense intracellular deposits in
Umod125R/125R mice. Nuclei counterstained with hematoxylin; scale bars: 25 µm. (F) Co-immunofluorescent labeling for uromodulin (red) and calnexin (green),
showing lack of colocalization in Umod+/+ kidneys, and partial and almost total colocalization in Umod+/125R and Umod125R/125R kidneys, respectively. Nuclei
counterstained with DAPI; scale bars: 25 µm.
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8-week-old females P<0.05) compared to Umod+/+ littermates
(Table 2). In addition, male Umod+/125R mice aged 8 weeks
(P<0.05) and male and female Umod+/125R mice aged 6 months
(P<0.05) had reduced urine osmolality, and 6-month-old male
Umod+/125R mice also excreted 1.5-times more urine (P<0.05)
compared to Umod+/+ littermates (Table 2). In 6-month-old
Umod125R/125R males and females (P<0.01), and Umod+/125R
males (P<0.05), this large excretion of dilute urine caused plasma
osmolality to rise and, in other mutant mice, plasma osmolalities
were inappropriately normal (Table 1). Thus, Umod+/125R and
Umod125R/125R mice have a urine concentrating defect, which is
similar to that reported in ADTKD-UMOD patients (Rampoldi
et al., 2003; Scolari et al., 2004).
Twenty-four hour uric acid excretion was decreased in 6-month-
old mice by up to ∼2.4-fold in Umod+/125R mice (males P<0.005;
females P<0.05), and up to∼4.8-fold inUmod125R/125R mice (males
P<0.005; females P<0.0001) compared to Umod+/+ littermates
(Table 2). In 8-week-old Umod125R/125R males, 24 h uric acid
excretion was also decreased by ∼1.6-fold compared to Umod+/+
male littermates (P<0.005) (Table 2). This was not due to the dilute
urine produced by these mice, since the 24 h excretion takes urine
volume into account. In 6-month-old mice, Umod+/125R and
Table 1. Plasma biochemistry in 8-week- and 6-month-old mice
Male Female
Parameter Umod+/+ Umod+/125R Umod125R/125R Umod+/+ Umod+/125R Umod125R/125R
8 weeks
n 8 8 8 9 9 9
Body weight (g) 25.8±0.3 26.1±0.4 26.5±0.6 19.8±0.2 20.7±0.5 20.1±0.8
Urea (mmol/l) 11.5±0.6 11.9±0.6 19.1±1.8$ 10.9±1.0 10.7±0.7 20.7±3.1**
Creatinine (µmol/l) 15.5±0.9 16.6±0.4 17.2±1.0 17.0±0.9 15.6±0.9 18.7±2.3
Pi (mmol/l) 3.4±0.1 3.4±0.2 3.3±0.2 3.2±0.2 3.6±0.2 3.4±0.2
ALP (U/l) 150.9±9.5 143.3±5.7 146.8±8.7 170.2±6.9 168.4±8.4 191.0±16.9
Corr.Ca (mmol/l) 2.85±0.03 2.83±0.03 2.77±0.05 2.71±0.03 2.68±0.03 2.77±0.04
Uric acid (µmol/l) 261.1±14.0 262.4±16.8 236.1±34.8 216.9±18.7 225.7±20.7 216.3±19.5
Osm (mOsm/kg) 345.9±3.6 347.1±2.6 353.6±1.7 351.7±2.8 350.0±2.5 356.3±4.3
6 months
n 10 12 6 7 8 8
Body weight (g) 32.6±0.9 32.4±0.6 32.9±1.1 27.6±1.0 27.7±1.5 27.0±0.9
Urea (mmol/l) 13.9±0.7 21.5±1.4$$,†† 36.4±2.6$$,†† 9.8±0.6 13.3±1.1**,† 20.7±1.0$$
Creatinine (µmol/l) 17.6±0.9 25.9±4.4* 31.3±4.1$,† 19.2±1.6 19.0±1.3† 23.7±1.2*,†
Pi (mmol/l) 2.5±0.1 2.8±0.1 2.9±0.2 2.7±0.2 3.1±0.3 2.6±0.1
ALP (U/l) 64.5±3.1 73.0±4.0 98.7±8.0$ 90.4±4.8 97.4±7.2 154.8±19.2**
Corr.Ca2+ (mmol/l) 2.64±0.02 2.74±0.04* 2.82±0.06** 2.60±0.05 2.72±0.05 2.83±0.03**
Uric acid (µmol/l) 164.1±9.0 181.3±18.3 140.8±11.0 193.6±29.9 207.5±11.5 185.9±25.0
Osm (mOsm/kg) 353.4±2.9 362.2±2.7* 369.3±2.9** 345.7±1.9 354.9±5.3 356.3±2.3**
Values are mean±s.e.m.; +/+, wild-types; +/125R, heterozygotes; 125R/125R, homozygotes; ‘n’ denotes number of mice; ALP, alkaline phosphatase; Corr.Ca,
calcium corrected for albumin; Osm, osmolality; Pi, inorganic phosphate. *P<0.05; **P<0.01; $P<0.001; $$P<0.0001 compared to wild-type mice of the same age
and sex. †P<0.05; ††P<0.0001 compared to 8-week-old mice of the same sex and genotype.
Table 2. Urinary parameters in 8-week- and 6-month-old mice
Male Female
Parameter Umod+/+ Umod+/125R Umod125R/125R Umod+/+ Umod+/125R Umod125R/125R
8 weeks
n 8 8 8 9 9 9
24 h vol/bw (µl/g) 99.5±5.0 102.3±10.7 173.1±7.1$ 66.7±7.7 66.8±7.1 143.5±10.1$
Osm (mOsm/kg) 2212±64 1960±78* 1322±90$ 2097±115 2330±84 1642±139*
Cr clear (ml/min) 0.43±0.03 0.40±0.02 0.40±0.03 0.24±0.03 0.29±0.04 0.28±0.04
FEUA (%) 0.74±0.02 0.70±0.07 0.60±0.11 1.56±0.41 1.16±0.17 1.00±0.17
24 h UA (nmol) 1165±70 1051±82 710±94** 910±84 988±139 802±111
24 h Ca (µmol) 3.47±0.30 4.12±0.47 4.46±0.58 1.99±0.24 3.26±0.64* 3.49±0.42**
pH 6.67±0.07 6.53±0.13 6.27±0.06** 6.48±0.08 6.31±0.08 5.94±0.05$
6 months
n 10 12 6 7 8 8
24 h vol/bw (µl/g) 76.3±7.6 98.8±6.7* 170.1±21.0$ 52.4±8.3 100.9±38.2 215.3±18.3$
Osm (mOsm/kg) 1581±118 1198±75* 657±42$ 2153±212 1653±182* 663±25$
Cr clear (ml/min) 0.31±0.04 0.25±0.04 0.16±0.06* 0.24±0.03 0.24±0.03 0.19±0.02
FEUA (%) 1.52±0.08 0.77±0.17** 0.54±0.20a,** 1.54±0.33 0.75±0.04* 0.46±0.13**
24 h UA (nmol) 1024±140 426±47** 213±67a,** 819±80 526±65* 197±39$
24 h Ca (µmol) 2.92±0.40 4.52±0.25** 4.28±0.80* 2.08±0.32 3.48±0.31** 4.65±0.24$
pH 6.51±0.08 5.71±0.07$ 5.79±0.09$ 6.50±0.13 5.90±0.10** 5.60±0.07$
Values are mean±s.e.m.; +/+, wild types; +/125R, heterozygotes; 125R/125R, homozygotes; ‘n’ denotes number of mice; 24 h vol/bw, 24 h urine volume (vol)
corrected for body weight (bw); Osm, osmolality; Cr clear, creatinine clearance; FEUA, fractional excretion of uric acid; 24 h UA, 24 h uric acid excretion; 24 h Ca,
24 h calcium excretion. an=4 because two of the urine samples were below the lower limit of detection for uric acid concentration. *P<0.05; **P<0.005; $P<0.0001
compared to wild-type mice of the same age and sex.
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Umod125R/125R male and female mice had a significantly (P<0.05 to
P<0.005) reduced FEUA, compared to Umod+/+ littermates
(Table 2). This specific reduction in uric acid excretion in
Umod+/125R and Umod125R/125R mice is analogous to the human
ADTKD-UMOD phenotype, in which >90% of patients have a
decreased FEUA (Williams et al., 2009).
Urinary calcium excretion was elevated by ∼1.6-fold (P<0.05)
and ∼1.8-fold (P<0.005) in 8-week-old female Umod+/125R and
Umod125R/125R mice, respectively, and elevated by ∼1.5-fold in
Umod+/125R (P<0.005) and Umod125R/125R (P<0.05) 6-month-old
males, and ∼1.6-fold (P<0.005) and ∼1.8-fold (P<0.0001) in
Umod+/125R and Umod125R/125R 6-month-old females, respectively,
when compared to Umod+/+ littermates (Table 2). This
hypercalciuria of Umod mutant mice, which has not been
described in human ADTKD-UMOD patients, was associated
with urinary acidification. Thus, urinary pH was significantly
reduced in 8-week-oldUmod125R/125R mice, corresponding to∼1.5-
fold (P<0.005) and ∼2.5-fold (P<0.0001) increases in urinary H+
ion concentrations in males and females, respectively, compared to
Umod+/+ littermates (Table 2). Six-month-old Umod+/125R and
Umod125R/125R mice also had a decreased urinary pH corresponding
to up to ∼5.3-fold (P<0.0001) and ∼7-fold (P<0.005) increases in
urinary H+ ion concentrations in males and females, respectively,
compared to Umod+/+ littermates (Table 2). This urinary
acidification helps to prevent renal stone formation, and is a likely
renal response to hypercalciuria (Renkema et al., 2009).
Uromodulin maturation, excretion and trafficking in 8-week-
and 6-month-old Umod+/125R and Umod125R/125R mice
The C126R uromodulin mutation results in defective maturation,
trafficking and secretion of uromodulin in vitro (Williams et al.,
2009), and we therefore carried out western blot analysis of kidney
lysates and urine, and immunohistochemistry, to study this inUmod
mutant mice. Kidney lysates from Umod+/+ mice showed the
presence of uromodulin at∼100 kDa as previously described (Bates
et al., 2004), corresponding to mature, fully glycosylated
uromodulin (Fig. 1C). Kidney lysates from Umod+/125R mice at
8 weeks and 6 months of age had mature uromodulin and a lower
molecular mass form of uromodulin, likely the ER-resident
precursor, which has core glycosylations only (Williams et al.,
2009). Kidney lysates from Umod125R/125R mice almost entirely
lacked mature uromodulin, with a predominance of the precursor
form of uromodulin. Higher molecular mass bands were detected in
kidney lysates from Umod+/125R and Umod125R/125R mice at
8 weeks and 6 months, at approximately double the molecular
mass of the precursor uromodulin; these may represent dimers of
precursor uromodulin, which would likely be retained in the ER
(Fig. 1C).
Urinary uromodulin excretion was studied by western blot and
densitometric analysis (Fig. 1D). Uromodulin is the most abundant
protein in the urine (Scolari et al., 2015); therefore, to enable
accurate western blot analysis, samples from Umod+/+ and
Umod+/125R mice were diluted 20-fold, but samples from
Umod125R/125R mice were not diluted. Sample loading was
standardized for equal creatinine concentration, to correct for the
more dilute urine in mutant mice. Eight-week-old male and female
Umod+/125R mice had a significantly reduced uromodulin excretion
of 66.8±3.3% and 69.1±4.5%, respectively, compared to Umod+/+
littermates (P<0.001) (Fig. 1D). This preceded the onset of renal
failure, as measured by an increase in plasma urea (Table 1).
Furthermore, this decrease in uromodulin excretion was
progressive, since both Umod+/125R and Umod125R/125R mice at
6 months old excreted significantly less uromodulin than mice of
the same sex and genotype aged 8 weeks (Fig. 1D). For example,
uromodulin excretion in male Umod+/125R mice decreased from
49.8±10.3% at 8 weeks of age to 15.7±2.9% at 6 months of age
when compared to Umod+/+ littermates (P<0.00001). All of the
excreted uromodulin was the mature form of uromodulin at
∼100 kDa, with no detectable excretion of the precursor form of
uromodulin.
Immunohistochemical analysis of uromodulin expression in
8-week- and 6-month-old Umod+/+, Umod+/125R and
Umod125R/125R kidneys showed the expected uromodulin
trafficking defect in mutant kidneys (Fig. 1E). In Umod+/+
kidneys, uromodulin expression had a predominantly apical
pattern, with low levels of diffuse intracellular uromodulin also
present as previously described (Kemter et al., 2009), and
uromodulin was observed in the tubular lumen. In Umod+/125R
and Umod125R/125R kidneys, apical expression was decreased,
and dense intracellular expression was observed, such that, in
Umod+/125R kidneys, uromodulin was partly apical and partly
intracellular, and, in Umod125R/125R kidneys, uromodulin was
almost exclusively located in dense intracellular deposits. Dual-
labeling for uromodulin and the ERmarker calnexin showed that the
intracellular uromodulin inUmod+/125R andUmod125R/125R kidneys
was colocalized with the ER (Fig. 1F), as previously demonstrated
both in vitro (Williams et al., 2009) and in ADTKD-UMOD patients
(Bernascone et al., 2010), and consistent with the presence of the
lower molecular mass precursor detected by western blotting
(Fig. 1C). In Umod+/125R mouse kidneys, uromodulin colocalized
with calnexin and was present at the apical membrane.
Renal fibrosis and immune cell infiltration in 8-week- and
6-month-old Umod+/125R and Umod125R/125R mice
Masson’s trichrome staining, to study renal damage and fibrosis,
of kidney sections from 8-week- and 6-month-old mice revealed
that, at 8 weeks, kidneys of Umod+/125R mice did not have any
abnormalities, but that kidneys of Umod125R/125R mice had
thickened basement membranes and some intracellular fibrous
deposits, similar to those reported in a renal biopsy from a patient
with a UMOD mutation (Nasr et al., 2008). Glomeruli appeared
normal in both Umod+/125R and Umod125R/125R mouse kidneys at
8 weeks of age (Fig. 2A). At 6 months of age, Umod+/125R mouse
kidneys had mild interstitial fibrosis, and Umod125R/125R mouse
kidneys had large areas of fibrosis, with some renal tubules
appearing to become detached from the basement membrane.
Furthermore, some glomeruli inUmod125R/125R mouse kidneys also
had increased fibrotic material, consistent with glomerulosclerosis
(Fig. 2A). No cysts were observed in Umod+/125R or Umod125R/125R
mouse kidneys at 8 weeks or 6 months of age.
During analysis of uromodulin-labeled and trichrome-stained
kidney sections, interstitial cell infiltrates were noted. To determine
the nature of these infiltrates, kidney sections were labeled for T-cell
(CD3) and macrophage (F4/80) markers. Umod+/125R mouse
kidneys at 8 weeks of age had no detectable immune cell
infiltration; however, Umod125R/125R mouse kidneys showed small
areas of interstitial infiltrates, consisting of T-cells and macrophages
(Fig. 2B,C). At 6 months of age, Umod+/125R mouse kidneys
showed small areas of interstitial T-cells and macrophages, but
Umod125R/125R mouse kidneys had multiple, large areas of
interstitial infiltrates, consisting of both T-cells and macrophages
(Fig. 2B,C). These infiltrates occurred mainly in the medullary
region, and often in close proximity to TAL cells expressing mutant
uromodulin.
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Upregulation of ER stress and UPR pathways in mutant TALs
Accumulation of mutant proteins in the ER may cause ER stress,
triggering an adaptive pathway called the unfolded protein response
(UPR). Members of the chaperone family of GRPs, and in particular
GRP78, are upregulated by the UPR in response to ER stress. We
therefore used immunohistochemistry of serial kidney sections to
investigate GRP78 expression in TAL cells expressing mutant
uromodulin. In Umod+/+ kidneys, GRP78 was expressed at a very
low level in non-TAL tubular epithelial cells, and at a slightly
elevated level in TAL tubular cells (Fig. 3A,B), a finding that was
confirmed in kidneys from an unrelated mouse line (data not
shown). However, in kidneys from both 8-week- and 6-month-old
Umod+/125R and Umod125R/125R mice, GRP78 expression was
upregulated specifically in TAL cells expressing mutant
uromodulin, and not in other tubular segments (Fig. 3A,B).
We sought to determine which of the three UPR pathways may be
active in TAL cells expressing mutant uromodulin, by
immunohistochemistry to detect expression of a member of each of
the three pathway, which are: ATF6α (ATF6α pathway), spliced
(active) XBP1 (XBP1S; IRE1 pathway) or ATF4 (PERK pathway).
None of the three pathwayswere upregulated in TALcells inUmod+/+
micewhen compared to non-TAL cells (Fig. 4A,B). No activation of
the ATF6α pathway was detected in Umod+/125R or Umod125R/125R
mice at either 8 weeks or 6 months of age, as there was no increase
in nuclear ATF6α expression in TAL cells (Fig. 4A,B). By
contrast, both XBP1S and ATF4 were upregulated in TAL cells of
Umod+/125R and Umod125R/125R mice compared to Umod+/+
littermates at both 8 weeks and 6 months of age (Fig. 4A,B),
demonstrating upregulation of the IRE1 and PERK pathways,
respectively, in response to retention of mutant uromodulin in the ER.
In order to quantify the upregulation of these ER stress and
UPR pathways, we microdissected TALs from Umod+/+ and
Umod125R/125R mice. Quantitative real-time PCR (qRT-PCR) analysis
for nephron segment-specific genes was undertaken to demonstrate
the purity of the obtained TALs (data not shown), followed by qRT-
PCR and western blot analyses for UPR components. qRT-PCR
Fig. 2. Fibrosis and inflammation in Umod+/+, Umod+/125R
and Umod125R/125R kidneys. (A) Masson’s trichrome stain in
the corticomedullary region at (i) 8 weeks and (ii) 6 months,
and (iii) in the cortex at 6 months, showing fibrous material
(blue). (B) Co-immunofluorescent labeling for uromodulin
(green) and the T-cell marker CD3 (red) at (i) 8 weeks and (ii)
6 months. Nuclei counterstained with DAPI. (C) Co-
immunofluorescent labeling for uromodulin (green) and the
macrophage marker F4/80 (red) at (i) 8 weeks and (ii)
6 months. Nuclei are counterstained with DAPI. All scale
bars: 50 µm.
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analysis showed that Xbp1S and Atf4 were significantly upregulated
by ∼1.9-fold (P<0.01) and ∼1.6-fold (P<0.001), respectively, in
Umod125R/125R TALs compared to Umod+/+ TALs, but that Grp78
and Atf6α expression levels were not significantly different
(Fig. 5A). However, western blot analysis showed that GRP78
protein was significantly upregulated by ∼4.2-fold (P<0.001) in
Umod125R/125R TALs compared to Umod+/+ TALs, consistent with
regulation of GRP78 expression at the translational level (Gulow
et al., 2002) (Fig. 5B,C). Interestingly, ATF6α was significantly
downregulated by ∼1.8-fold (P<0.05) in Umod125R/125R TALs
compared to Umod+/+ TALs (Fig. 5B,C). XBP1S and ATF4 were
significantly upregulated by ∼13.6-fold (P<0.001) and ∼4.5-fold
(P<0.01), respectively, in Umod125R/125R TALs (Fig. 5B,C),
confirming the results obtained by immunohistochemical analysis.
Upregulation of the PERK pathway via ATF4 is associated with
suppression of general protein translation but induction of expression
of specific UPR target genes, such as CCAAT/enhancer-binding
protein homologous protein (CHOP) (Hetz, 2012). qRT-PCR
analysis of isolated TALs showed that Umod mRNA was
downregulated by ∼6.6-fold (P<0.001) in Umod125R/125R TALs
compared toUmod+/+ TALs (Fig. 5A).ChopmRNAwas upregulated
by ∼2.2-fold (P<0.001) in Umod125R/125R TALs compared to
Umod+/+ TALs (Fig. 5A), and immunohistochemical analysis of
serial kidney sections confirmed that CHOP protein was upregulated
in TAL cells in Umod+/125R and Umod125R/125R mice compared to
Umod+/+ littermates at both at 8 weeks and 6 months of age, as shown
by accumulation of CHOP in the nuclei of TAL cells (Fig. 6A,B).
Increased CHOP expression may lead to apoptosis (Hetz, 2012);
however, analysis of kidney sections using terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay and co-staining
for uromodulin showed that, as inUmod+/+ littermates, there were no
TUNEL-positive TAL cells in Umod+/125R and Umod125R/125R
mouse kidneys at either 8 weeks or 6 months of age (Fig. 6A,B).
However, occasional TUNEL-positive cells were detected in other
segments, demonstrating that the assay was functional. Thus,
mechanisms other than apoptosis are likely responsible for tubular
damage in Umod+/125R and Umod125R/125R mice.
DISCUSSION
Wehave generated amouse model with an ADTKD disease-causing
UMOD mutation, that displays: defective uric acid excretion;
urinary concentrating defects; renal failure; defective uromodulin
trafficking, maturation and secretion; renal fibrosis; interstitial
immune cell infiltration; and ER stress with upregulation of the UPR
in the TAL. This model is representative of ADTKD-UMOD
patients, who develop hyperuricemia, low FEUA and gout, chronic
renal failure, tubulointerstitial nephropathy, glomerulosclerosis and
lymphocytic infiltration (Lhotta et al., 1998; Turner et al., 2003).
Thus, this mouse provides an in vivomodel to study mechanisms of
renal fibrosis and ER stress.
A major feature of ADTKD-UMOD in humans is hyperuricemia,
which was not present in Umodmutant mice. This is not surprising,
as mice express the hepatic enzyme uricase (urate oxidase),
which catalyses low solubility uric acid to the high solubility
allantoin; uricase has been evolutionarily silenced in humans
and other primates (Wu et al., 1992). However, Umod+/125R and
Umod125R/125R mice, similar to ADTKD-UMOD patients, still
demonstrated significant decreases in both FEUA and 24 hour uric
acid excretion. Interestingly, in female Umod125R/125R mice, this
decreased uric acid excretion was detected after the onset of renal
failure, as measured by a significantly increased plasma urea, since
8-week-old Umod125R/125R females had an elevated plasma urea,
but a similar uric acid excretion compared to Umod+/+ females. The
role of plasma uric acid levels in the pathogenesis of ADTKD-
UMOD has been the subject of much debate, particularly whether
drugs that lower plasma uric acid can slow the progression of
ADTKD-UMOD in patients (Bleyer and Hart, 2003; Fairbanks
et al., 2002, 2004; Puig et al., 2006; Puig and Torres, 2003, 2004).
Fig. 3. ER stress in Umod+/+, Umod+/125R and
Umod125R/125R kidneys. Immunohistochemical
staining of serial sections for uromodulin and GRP78
in (A) 8-week-old and (B) 6-month-old mice, showing
increased expression of GRP78 specifically in TAL
cells expressing mutant uromodulin in Umod+/125R
and Umod125R/125R kidneys. Nuclei counterstained
with hematoxylin; scale bars: 50 µm.
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Our model demonstrates that hyperuricemia is a secondary
consequence of the other phenotypes of ADTKD-UMOD (e.g.
decreased uric acid excretion, renal failure and kidney histopathology),
and is not required to cause the renal pathophysiology, since our
model develops these other phenotypes without hyperuricemia.
However, hyperuricemia may help to propagate or enhance the
disease progression in humans, and this hypothesis could be tested in
our model by using uricase inhibitors.
The mechanism of decreased uric acid excretion is not fully
understood, but may be a consequence of the urine concentrating
defect. In the normal TAL, the water impermeability is likely due to
the presence of uromodulin in a gel-like structure at the apical plasma
membrane, which is permeable to ions but not to water (Mattey and
Naftalin, 1992). In Umod+/125R and Umod125R/125R mice, retention
of the mutant uromodulin protein in the ER of the TAL cells would
decrease the amount of uromodulin at the apical plasma membrane,
and may compromise this water impermeability. This may lead to a
reduction in the normally high osmolality of the medullary
interstitium, thus inhibiting water reabsorption in the collecting
duct (CD), and resulting in a more dilute urine (Devuyst et al., 2005).
The previously reported Umod−/− knock-out mice also have a urine
concentrating defect (Bachmann et al., 2005). This defect in urine
concentration due to alterations of TAL characteristics may be
analogous to patients treated with loop diuretics, such as those with
hypertension, who also develop secondary hyperuricemia (Ramsay
et al., 1994). Loop diuretics (e.g. furosemide) specifically inhibit the
TAL Na+:K+:2Cl− (NKCC2) transporter, decreasing water
reabsorption with a consequent increase in urine volume (Gamba
and Friedman, 2009). During loop diuretic treatment, the resulting
decrease in extracellular fluid (ECF) volume causes increased
sodium reabsorption by the proximal convoluted tubule (PCT),
which likely drives increased uric acid reabsorption, hence causing
the hyperuricemia which is often associated with these drugs
(Weinman et al., 1975). A possible compensatory mechanism for
excess water loss has been described inUmod−/− knock-out mice by
upregulation of several critical TAL ion transporters, including the
target of loop diuretics, NKCC2, which is usually activated by
uromodulin (Bachmann et al., 2005). Thus, similar mechanisms may
Fig. 4. Analysis of UPR pathways in Umod+/+, Umod+/125R and Umod125R/125R kidneys. Immunohistochemical staining of serial sections for uromodulin,
ATF6α, ATF4 and spliced (active) XBP1 (XBP1S) in (A) 8-week-old and (B) 6-month-old mice, showing upregulation of ATF4 and XBP1S specifically in TAL cells
expressing mutant uromodulin in Umod+/125R and Umod125R/125R kidneys, but no upregulation of ATF6α. Nuclei counterstained with hematoxylin; scale bars:
50 µm.
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be responsible for hyperuricemia in loop diuretic-treated
hypertensive patients and ADTKD-UMOD patients; this requires
further investigation in Umod+/125R and Umod125R/125R mice.
The urine concentrating defect described in Umod−/− knock-out
mice (Bachmann et al., 2005) and Umod+/125R and Umod125R/125R
mice in this study is likely due to the absence of uromodulin at the
apical plasma membrane of the TAL. However, Umod−/− knock-out
mice do not develop any histological characteristics of ADTKD-
UMOD, or renal failure (Raffi et al., 2006). Thus, mutant uromodulin
protein must be present to cause the renal pathology associated with
ADTKD-UMOD, and we have shown that histopathological changes
characteristic of human ADTKD-UMOD patients, such as interstitial
fibrosis and immune cell infiltration, are present in ourUmod+/125R and
Umod125R/125R knock-in mice. Uromodulin is the most abundant
protein in the urine, and is expressed only by the TAL (Scolari et al.,
2015), indicating a high rate of uromodulin expression in TAL cells.
Thus, even though cells possess mechanisms to degrade misfolded
proteins, such asERAD, the highexpression rate ofmutant uromodulin
over time may overwhelm such mechanisms. Uromodulin can also
stimulate the innate and adaptive immune systems (Säemann et al.,
2005b;Su et al., 1997).Thus, it hasbeenpostulated that kidneydamage
may compromise its integrity and allow uromodulin to be exposed to
the immune system, which may cause antibody production (Säemann
et al., 2005b), as well as inflammation and/or immune cell infiltration,
which can result in fibrosis of the kidney (Eddy, 2014).
Umod+/125R and Umod125R/125R mice have several phenotypic
characteristics that are similar to those reported for the C147W
uromodulin transgenic (TgUmodC147W) mouse model, including
renal failure, urinary concentrating defects, fibrosis, immune cell
infiltration and intracellular uromodulin retention. However,
Umod+/125R and Umod125R/125R mice had a selective defect in
renal uric acid handling that was not studied in TgUmodC147W
transgenic mice (Bernascone et al., 2010), whereas TgUmodC147W
mice had renal cysts, which were not detected in Umod+/125R or
Umod125R/125R mice (Table S1). The reason for these differences
between Umod125R mice and TgUmodC147W mice remains to be
elucidated, but there are several possible explanations. First,
these differences may involve strain-specific factors, as the
TgUmodC147W mice were generated on an FVB background, whilst
the Umod125R mice were on a C57BL/6 background. Second, the
TgUmodC147W mice are a transgenic model that express Umod at
higher levels than wild-type mice without the transgene, whereas, in
Umod125R mice, the mutant Umod directly replaces the wild-type
allele. Third, TgUmodC147W mice express mutant uromodulin with a
different mutation compared to Umod125R mice. Patients with
different mutations have marked variations in some phenotypic
features, such as rate of progression to ESRF (Moskowitz et al.,
2013); however, this does not seem to be true of hyperuricemia,
which is present in >90% of patients (Williams et al., 2009). The
presence or absence of cysts is the most variable phenotype
associated with ADTKD-UMOD in humans and may only be found
in <15% of patients (Williams et al., 2009). Indeed, different
members of the same family may have variable cyst formation
(Rampoldi et al., 2003; Vylet’al et al., 2006); this variation may be
due to other genetic differences or environmental factors rather than
to different UMOD mutations. Cysts have not been reported in
Fig. 5. Expression of ER stress and UPR pathway components in isolatedUmod+/+ (WT) andUmod125R/125R (hom) TALs. (A) qRT-PCR analysis ofGrp78,
Atf6α, spliced (active)Xbp1 (Xbp1S), Atf4,Chop andUmod. Gene expression changes are relative toGapdh and expressed as a fold change overWTexpression
(mean set to 1). Individual TAL preparations (n=6-11) from 2-4 mice per group are represented as single points; mean±s.e.m. are displayed to the right of each
data set; **P<0.01, ***P<0.001 versus WT, using 2-tailed Mann–Whitney U-test. (B) Representative western blots and (C) quantification of GRP78, ATF6α,
XBP1S and ATF4. Protein was normalized for loading using β-actin and quantification is expressed as a fold change over WT expression (mean set to 1).
Individual TAL preparations (n=8-11) from 3-4 mice per group are represented as single points; mean±s.e.m. are displayed to the right of each data set; *P<0.05,
**P<0.01, ***P<0.001 versus WT, using 2-tailed Mann–Whitney U-test.
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families with either the C126R or C148W mutations (Lhotta et al.,
1998; Rampoldi et al., 2003), and the basis for this variation in cyst
formation between different families, family members and mouse
models requires further investigation. Two ENU-mutagenized
mouse models, carrying A227T or C93F uromodulin mutations
on the same backgrounds, have recently been described to have
differing rates of disease onset and progression, with C93F mutant
mice having the more severe phenotype (Kemter et al., 2013). The
ENU mutant mice both displayed decreased uric acid excretion that
was present in Umod125R mice but absent in TgUmodC147W mice,
tubulocystic changes that were present in TgUmodC147W mice but
absent in Umod125R mice, and glomerulocystic changes that were
absent in both TgUmodC147W andUmod125R mice (Bernascone et al.,
2010; Kemter et al., 2013) (Table S1). These differences between
the germline Umod125R, transgenic TgUmodC147W and ENU A227T
and C93F mice with different mutations highlight the advantages of
having multiple mouse models that provide the opportunity of
elucidating further the relationships between protein, uromodulin
mutation, genetic modifiers, phenotype and mechanism in
ADTKD-UMOD.
Our results provide mechanistic insights by showing that ER
stress is present in TAL cells expressing mutant uromodulin, and
that two of the three UPR pathways (PERK and IRE1) are active,
leading to upregulation of CHOP. However, this did not lead to
apoptosis of TAL cells, demonstrating that other mechanisms may
be responsible for TAL damage, and consequent fibrosis and
immune cell infiltration, in this model. CHOP is a transcription
factor typically thought to upregulate pro-apoptotic pathways;
however, it may also be protective under certain conditions in
different cell types. For example, mice with autosomal dominant
retinitis pigmentosa due to ER retention of mutant rhodopsin have
retinal damage that is associated with UPR and CHOP upregulation;
however, deletion of CHOP led to increased retinal damage in these
mice, suggesting a protective role for CHOP (Nashine et al., 2013).
Several studies have implicated ER stress, leading to CHOP
expression and apoptosis, in models of renal disease. However,
these studies have primarily investigated the renal response to toxins
(e.g. high glucose in diabetic nephropathy or high albumin levels to
mimic proteinuria), drugs (e.g. acetaminophen) or acute renal injury
(e.g. using unilateral ureteric obstruction), or have focused on
glomerular injury (Dickhout and Krepinsky, 2009). Relatively little
work has been carried out to understand the role of chronic ER stress
in renal tubule cells endogenously expressing an ER-retained
mutant protein, and our mouse model for ADTKD-UMOD will be
an important resource for further studies in this area. Active XBP1
protein was also upregulated in TAL cells in Umod125R mice,
Fig. 6. Analysis of CHOP expression and apoptosis
in Umod+/+, Umod+/125R and Umod125R/125R kidneys.
Immunohistochemical staining for uromodulin and
CHOP, and co-immunofluorescence using TUNEL
assay to label apoptotic cells (green) and anti-
uromodulin antibody to label TAL cells (red), in serial
sections in (A) 8-week-old and (B) 6-month-old mice.
CHOP is upregulated in the nuclei of TAL cells
expressing mutant uromodulin in Umod+/125R and
Umod125R/125R kidneys, but there is an absence of
apoptosis in TAL cells. Nuclei counterstained with
hematoxylin (immunohistochemistry) or DAPI
(immunofluorescence); scale bars: 50 µm.
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demonstrating upregulation of the IRE1 pathway, and this may also
be an adaptive or apoptotic response to ER stress (Ghosh et al.,
2014). During prolonged ER stress, PERK signaling is maintained
whilst IRE1 signaling is attenuated, whichmay lead to a switch from
adaptive to apoptotic signaling (Lin et al., 2007). Consistent with
this hypothesis, prolonged IRE1 signaling enhanced cell
proliferation and prevented apoptosis when human embryonic
kidney (HEK)293 cells were exposed to the UPR inducers
tunicamycin and thapsigargin (Lin et al., 2007, 2009). In
Umod125R mice, both the PERK and IRE1 pathways appeared to
be active even at 6 months of age, and the presence of both of these
pathways may explain the absence of the apoptotic response in TAL
cells in these mice. Studies of the transgenic TgUmodC147Wmice also
showed an absence of apoptosis by a lack of active caspase-3
staining; thus, apoptosis does not appear to play a significant role in
tubule damage in ADTKD-UMOD (Bernascone et al., 2010).
In conclusion, we have generated a mouse model for a monogenic
cause of renal fibrosis carrying an ADTKD-UMOD disease-causing
mutation, C125R, in the endogenous mouse Umod gene.
Umod+/125R and Umod125R/125R mice demonstrate several of the
phenotypes of human ADTKD-UMOD patients, including
progressive renal failure, urine concentrating defects, decreased
uric acid and uromodulin excretion, retention of uromodulin in the
ER, and pathological changes in the kidney such as fibrosis,
immune cell infiltration and ER stress. The PERK and IRE1 UPR
pathways were found to be specifically upregulated in TAL cells of
Umod+/125R and Umod125R/125R mice, which was associated with
upregulation of CHOP; however, this did not lead to apoptosis. This
novel knock-in mouse model will be a valuable resource to study the
mechanisms of pathogenesis and progression of renal fibrosis,
ESRF and ADTKD-UMOD, and to test novel therapeutic agents for
these diseases.
MATERIALS AND METHODS
Generation of knock-in targeting vector and mutant mice
Exon 3 of mouse Umod was amplified by PCR and used to screen a mouse
PAC library (MRC Geneservice, Cambridge, UK). A PAC containing
mouse Umod was then used as a template in a long-range PCR reaction to
amplify an ∼7.6 kb product between the 5′ upstream region and intron 5 of
Umod. Exon and intron-exon boundary sequences were verified by direct
DNA sequencing as described (Nesbit et al., 2004). After insertion into
pGEM-T (Promega, Southampton, UK), site-directed mutagenesis (SDM)
was performed to introduce the C125R mutation as described (Nesbit et al.,
2004); during this procedure, a novel BsoBI restriction site was also
generated. SDM was also used to introduce a HindIII site into intron
2. Following each round of SDM, the sequences of exons and intron-exon
boundaries were verified by direct DNA sequencing. A neomycin resistance
(NeoR) cassette flanked by two loxP sites was excised from plasmid
pmmneoflox8 and cloned into intron 2 of Umod using XbaI and HindIII.
Plasmid pBSTK, containing a thymidine kinase (TK) cassette, was
mutagenized by SDM to introduce a SfiI restriction site, and the TK
cassette was inserted into the targeting vector at the 5′ end of theUmod gene
using SfiI and SacII (Fig. S1). The vector was linearized using SbfI,
electroporated into the R1 embryonic stem (ES) cell line, and cells selected
using 300 µg/ml G418 (Geneticin, Gibco, Paisley, UK) and 0.2 µM
gancyclovir (Calbiochem, Manchester, UK). Cells in which homologous
recombination had occurred at both the 5′ and 3′ arms were identified by
PCR/restriction digest and Southern blot analysis (Harding et al., 2009) as
follows: 5′ PCR: forward primer in the 5′ region outside the vector and
reverse primer within the NeoR cassette generated a 2.8 kb product in
recombined clones only; 3′ PCR: forward primer within exon 3 and reverse
primer within intron 5 (outside the vector) generated a 5.3 kb fragment in all
clones, which, when digested with BsoBI, generated an extra fragment in
recombined clones; 5′ Southern blot: digestion with PflFI and a probewithin
the 5′ upstream region detected an ∼11.6 kb Umod wild-type fragment and
an ∼7.4 kb Umod mutant fragment; 3′ Southern blot: digestion with SpeI
and a probe corresponding to exon 6 of Umod detected an ∼8.3 kb Umod
wild-type fragment and an ∼9.6 kb Umod mutant fragment (Fig. 1A). ES
cells heterozygous for the mutation were injected into C57BL/6 blastocysts
at embryonic day 2.5, which were transferred into the uterus of
pseudopregnant C57BL/6 females. Male chimeras were mated with
C57BL/6 females and the offspring tested for germline transmission by
extraction of DNA from ear biopsy material in DNA extraction buffer
(50 mM Tris pH 8.5, 1 mM EDTA, 0.5% Tween-20, with 50 µg Proteinase
K), followed by PCR and BsoBI digestion. The NeoR cassette was excised
between loxP sites by mating with β-actin-Cre mice, and the removal of the
NeoR cassette was verified by PCR assay. Mice were backcrossed to the
C57BL/6J background strain and mice from backcross (BC)3-BC5 were
used for studies in 6-month-old mice, and from BC4-BC7 for studies in
8-week-old mice. Animals were maintained according to local welfare
guidelines, and all procedures were carried out under UK Home Office
personal and project license restrictions.
Metabolic cage analysis
Eight-week- and 6-month-old Umod+/+, Umod+/125R and Umod125R/125R
littermates were investigated in individual metabolic cages (Techniplast) for
24 h with free access to food and water. Body weight, water intake and
urine output were measured and urine was collected under mineral oil. Mice
were euthanized by terminal anesthesia, blood collected via the jugular
vein, and plasma obtained by centrifugation at 800 g for 10 min. Plasma
and urine biochemical analysis was performed on a Beckman Coulter
AU680 semi-automated clinical biochemistry analyzer as described (Piret
et al., 2012), and plasma calcium was corrected for albumin (Corr.Ca) using
the formula: Corr.Ca=Ca(mmol/l)−[(Alb(g/l)−30)×0.017] (Piret et al.,
2012). Osmolalities were measured using a Model 3320 Osmometer
(Advanced Instruments Inc., Norwood, MA, USA) and urinary pH was
measured using a Microprocessor pH meter (Hanna Instruments, Leighton
Buzzard, UK).
Western blot analysis of whole kidney lysates and urine
Uromodulin maturation and excretion in Umod+/+, Umod+/125R and
Umod125R/125R mutant mice were studied by western blot analysis of
kidney lysates and urine samples. Kidneys were homogenized in β-
octylglucoside lysis buffer [20 mM Tris-HCl pH 8; 150 mM NaCl; 60 mM
β-octylglucoside (Bernascone et al., 2010)] with a protease inhibitor
cocktail (Roche, Burgess Hill, UK). Insoluble material was removed by
centrifugation, total protein concentration of the soluble fraction determined
using the micro BCA Protein Assay (Pierce, UK) (Bernascone et al., 2010;
Williams et al., 2009), and lysates loaded at 20-50 µg total protein per lane.
Urine samples were normalized to urinary creatinine such that, for Umod+/+
and Umod+/125R samples, a urine volume corresponding to 0.5 nmol
creatinine was loaded and, for Umod125R/125R samples, a urine volume
corresponding to 10 nmol was loaded. Western blotting and densitometric
analysis were performed as previously described, using sheep anti-
uromucoid antibody (Biodesign International, Saco, ME, USA), or rabbit
anti-tubulin antibody (Abcam ab15246, 1:500), followed by horseradish
peroxidase (HRP)-conjugated mouse anti-sheep (Sigma, Poole, UK) or
HRP-conjugated goat anti-rabbit (Bio-Rad, Watford, UK) antibodies,
respectively (Williams et al., 2009). To control for variances between
blots of urinary uromodulin, at least two Umod+/+ samples were loaded on
each gel, a standard ‘remove background’ tool was used prior to
quantification by densitometry, and mean densities of Umod+/+ bands
were set to 100% for comparison with other bands on the same blot.
Histological and immunohistochemical analysis
Kidneys were dissected and fixed in 10% neutral buffered formalin for 24 h,
then dehydrated, paraffin embedded and sectioned at 5 µm thickness.
Trichrome staining was carried out according to standard protocols. For
immunohistochemical labeling, sections were rehydrated, then subjected
to antigen unmasking either by incubation in 20 µg/ml proteinase K for
5-15 min, or by heat-mediated antigen retrieval in either pH 6, pH 9 or pH
783
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10 buffers. Sections were blocked in pre-immune serum, and probed with
the following primary antibodies: sheep anti-uromucoid (Biodesign
International, 1:500); rabbit anti-calnexin (Abcam ab22595, 1:50); rabbit
anti-CD3 (Abcam ab16669, 1:50); rat anti-F4/80 (Serotec clone A3-1,
1:50); rabbit anti-GRP78 (Abcam ab21685, 1:1000); rabbit anti-ATF4
(Abcam ab105383, 1:500); rabbit anti-ATF6α [Santa Cruz Biotechnology
(Santa Cruz, CA, USA) sc-22799, 1:50]; goat anti-XBP1 (spliced) (Abcam
ab85546, 1:100); or rabbit anti-CHOP (Santa Cruz sc-575, 1:50). Secondary
detection was achieved by: HRP-conjugated donkey anti-sheep antibody
(Jackson ImmunoResearch, 1:500) visualized using the 3,3′-
Diaminobenzidine (DAB) reaction kit (Vector Labs, Peterborough, UK)
for uromodulin; the DAKO Envision+ System DAB kit for rabbit primary
antibodies; the Santa Cruz ABC staining system for goat primary antibodies;
or fluorescently conjugated donkey secondary antibodies (Jackson
ImmunoResearch or Invitrogen) for dual-labeling. TUNEL assay was
performed using the ApopTag Fluorescein kit (Millipore, Hertfordshire,
UK) according to the manufacturer’s instructions. DAB-stained slides
were counterstained with hematoxylin, and fluorescently labeled slides were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Slides were
examined by light or UV microscopy using an Eclipse E400 microscope
(Nikon, Japan), and images were captured using a DXM1200C digital
camera, with an original magnification of 20× or 40×, and NIS-Elements
BR2.30 software (both Nikon). Immunohistochemistry was performed on 2
kidney sections from each of 4 mice per group.
Isolation ofmouseTALs, and qRT-PCRandwestern blot analyses
Mouse TALs were isolated following a previously described protocol
(Glaudemans et al., 2014) with minor modifications. Briefly, 2- to 3-month-
old male Umod+/+ and Umod125R/125R mice were sacrificed by cervical
dislocation. Kidneys were removed, decapsulated and placed in ice-cold
dissection solution (Hanks balanced salt solution with 15 mM HEPES,
10 mM D-glucose, 5 mM glycine, 1 mM L-alanine, adjusted to
325 mOsm/kgH2O with mannitol and pH 7.4 with NaOH). Each kidney
was cut into 2 equal parts by a midsagittal section and then into thin
transverse slices that were further cut into radial corticomedullary stripes.
Kidney pieces were digested for 30 min in dissection solution supplemented
with 245 U/ml type 2 collagenase (Worthington Biochemical Corporation,
Lakewood, NJ, USA) and 96 µg/ml soybean trypsin inhibitor (Sigma-
Aldrich) at 37°C on a shaker. The supernatant containing small kidney
fragments and isolated tubules was sieved through 250 µm and 50 µm filters
(Sefar AG, Heiden, Switzerland) and tubules retained on the 50 µm filter
were collected in 37°C dissection solution supplemented with 1% BSA
(Sigma-Aldrich) and 96 µg/ml soybean trypsin inhibitor (Sigma-Aldrich).
Remaining undigested kidney fragments were digested for 10 min in fresh
collagenase solution. TALs were manually selected under a light
microscope using a glass pipet connected to a micromanipulator
(Narishige International, London, UK). Total RNA was extracted from
microdissected TALs using RNAqueous® Total RNA Isolation Kit
(Invitrogen, MA, USA), following the manufacturer’s protocol, and
DNAseI treatment performed. The reverse transcriptase (RT) reaction was
performed using 1 µg of RNA and the iScript™ cDNA Synthesis Kit (Bio-
Rad). Changes in mRNA levels of target genes were determined by relative
qRT-PCR with a CFX96™ Real-Time PCR Detection System (Bio-Rad)
using iQ™ SYBR Green Supermix (Bio-Rad) detection of single PCR
product accumulation in duplicate. Specific primers were designed using
Primer3. PCR conditions were 95°C for 3 min followed by 40 cycles of 15 s
at 95°C, 30 s at 60°C. PCR products were sequenced using the BigDye
Terminator Kit (Perkin Elmer Applied Biosystems, MA, USA), purified
using the multiScreen SEQ384 Filter Plate (Millipore) and Sephadex G-50
DNA Grade Fine (Amersham Biosciences, NJ, USA), and analyzed on an
ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). The
efficiency of each set of primers was determined by dilution curves.
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used routinely as
a reference gene. Relative changes in target gene/Gapdh mRNA ratio were
determined by the formula: 2ΔΔct. For western blot analysis, 50-70 TALs
were pooled and directly transferred in 4× Laemmli sample buffer (Bio-Rad)
supplemented with protease inhibitors (Roche, Basel, Switzerland) and
60 mg/ml dithiothreitol (AppliChem), and boiled at 95°C for 5 min.
Western blotting and densitometric analysis were performed using
antibodies against ATF4, ATF6α, GRP78 and spliced XBP1, as above.
Statistical analysis
Statistical analyses were performed using Student’s unpaired t-test or the
Mann–Whitney U-test, where appropriate.
Study approval
All animal studies were approved by the University of Oxford Ethical
Review Committee and were licensed under the Animals (Scientific
Procedures) Act 1986, issued by the United Kingdom Government Home
Office Department.
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Säemann, M. D., Weichhart, T., Zeyda, M., Staffler, G., Schunn, M., Stuhlmeier,
K. M., Sobanov, Y., Stulnig, T. M., Akira, S., von Gabain, A. et al. (2005b).
Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive
immunity via a Toll-like receptor-4-dependent mechanism. J. Clin. Invest. 115,
468-475.
Scolari, F., Caridi, G., Rampoldi, L., Tardanico, R., Izzi, C., Pirulli, D., Amoroso,
A., Casari, G. and Ghiggeri, G. M. (2004). Uromodulin storage diseases: clinical
aspects and mechanisms. Am. J. Kidney Dis. 44, 987-999.
Scolari, F., Izzi, C. and Ghiggeri, G. M. (2015). Uromodulin: from monogenic to
multifactorial diseases. Nephrol. Dial. Transplant. 30, 1250-1256.
Su, S. J., Chang, K. L., Lin, T. M., Huang, Y. H. and Yeh, T. M. (1997). Uromodulin
and Tamm-Horsfall protein induce humanmonocytes to secrete TNF and express
tissue factor. J. Immunol. 158, 3449-3456.
Takiue, Y., Hosoyamada, M., Yokoo, T., Kimura, M., Ochiai, M., Kaneko, K.,
Ichida, K., Hosoya, T. and Shibasaki, T. (2008a). Production and
characterization of transgenic mice harboring mutant human UMOD gene.
Nucleosides Nucleotides Nucleic Acids 27, 596-600.
785
RESEARCH ARTICLE Disease Models & Mechanisms (2017) 10, 773-786 doi:10.1242/dmm.029488
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Takiue, Y., Hosoyamada, M., Yokoo, T., Kimura, M. and Shibasaki, T. (2008b).
Progressive accumulation of intrinsic mouse uromodulin in the kidneys of
transgenic mice harboring the mutant human uromodulin gene. Biol. Pharm.
Bull. 31, 405-411.
Trudu, M., Janas, S., Lanzani, C., Debaix, H., Schaeffer, C., Ikehata, M., Citterio,
L., Demaretz, S., Trevisani, F., Ristagno, G. et al. (2013). Common noncoding
UMOD gene variants induce salt-sensitive hypertension and kidney damage by
increasing uromodulin expression. Nat. Med. 19, 1655-1660.
Tsang, K. Y., Chan, D., Bateman, J. F. and Cheah, K. S. E. (2010). In vivo cellular
adaptation to ER stress: survival strategies with double-edged consequences.
J. Cell Sci. 123, 2145-2154.
Turner, J. J. O., Stacey, J. M., Harding, B., Kotanko, P., Lhotta, K., Puig, J. G.,
Roberts, I., Torres, R. J. andThakker, R. V. (2003). UROMODULINmutations cause
familial juvenile hyperuricemic nephropathy. J.Clin. Endocrinol.Metab.88, 1398-1401.
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